Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBK | Q96KB5 | 5/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 2/20 | 0.37 |
| ▸ | INSR | P06213 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.37 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16908183 | 0.93 | PBK (0.53) | PBKCCNB2CDK1CCNB1GSK3B | |
| SCHEMBL15646739 | 0.81 | PBK (0.53) | PBKCCNB2CDK1CCNB1GSK3B | |
| SCHEMBL15646740 | 0.79 | PBK (0.52) | PBKCCNB2CDK1CCNB1GSK3B | |
| SCHEMBL16897060 | 0.78 | PBK (0.52) | PBKCCNB2CDK1CCNB1GSK3B | |
| SCHEMBL15644673 | 0.78 | PBK (0.52) | PBKCCNB2CDK1CCNB1GSK3B | |
| Acetic Acid SCHEMBL15646249 | 0.77 | CIT (0.40) | BTKCHUKINSRMAPK8CAMKK2 | |
| Acetic Acid SCHEMBL28045010 | 0.73 | CIT (0.44) | MEN1KMT2AL3MBTL1CHUKINSR | |
| SCHEMBL8233927 | 0.72 | CCNB2 (0.60) | PBKCCNB2CDK1CCNB1GSK3B | |
| SCHEMBL8235718 | 0.70 | PBK (1.00) | PBK | |
| SCHEMBL16908237 | 0.70 | CCNK (0.44) | CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129372-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9896446-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| EP-3129372-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Cancer Research Technology Limited (GB) | 2017-02-15 | — | — | EP | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| WO-2015148597-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | WINDTREE THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| EP-2900666-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Ignyta, Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | PBK 609/4885CCNB2 2412/4885CDK1 506/4885 |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | PBK 652/4885CCNB2 2171/4885CDK1 501/4885 |
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | PRKCQ, PRKCA, PRKCZ | PBK 910/4885CCNB2 1622/4885CDK1 358/4885 |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | PRKCQ, PRKCA, PRKCZ | PBK 910/4885CCNB2 1622/4885CDK1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.